PARP INHIBITORS - COMPETITIVE LANDSCAPE, PIPELINE AND MARKET ANALYSIS, 2018
This report can be delivered to the clients within 48 hours
'PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 15+ products along with 12+ companies involved. AbbVie and Pfizer are among the developers of most promising pipeline products.
Products covered by Phase
Pipeline analysis of 15+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for PARP Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'PARP Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 15+ products along with 12+ companies involved. AbbVie and Pfizer are among the developers of most promising pipeline products.
Products covered by Phase
- Marketed Products
- Phase III, Phase II and Phase I
- IND and Pre-clinical
Pipeline analysis of 15+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for PARP Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of PARP Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for PARP Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the PARP Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for PARP Inhibitors and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario PARP Inhibitors to formulate effective R&D strategies
- Assess challenges and opportunities that influence PARP Inhibitors R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding PARP Inhibitors pipeline depth and focus of target therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for PARP Inhibitors to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Executive Summary
Collaboration, Acquisitions and LicensingTable of Contents
Overview
Poly (ADP-Ribose) Polymerase
Structure and Function of PARP1
PARP Homologs
Functions of PARP
Role in DNA Repair
Function in Chromatin Remodeling
Effects on Transcription Factors and Epigenetic Factors
PARP Inhibitor
Market Overview
Comparative Analysis of Pipeline & Marketed Products
Marketed Drug Candidate Profiles
Zejula: Tesaro
Product Description
Research and Development
Zejula Heat Map
Product Development Activities
Zejula Heat Map
Forecasted Sales for Zejula
Zejula Analyst Insights
(The list continues)
Market Positioning of PARP Inhibitors
PARP Inhibitors Market Evolution
PARP Inhibitors Class Share Evolution
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Veliparib: Abbvie
Product Description
Research and Development
Product Development Activities
Forecasted Sales for Veliparib
Veliparib Analyst Insights
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Appendix
Collaboration, Acquisitions and LicensingTable of Contents
Overview
Poly (ADP-Ribose) Polymerase
Structure and Function of PARP1
PARP Homologs
Functions of PARP
Role in DNA Repair
Function in Chromatin Remodeling
Effects on Transcription Factors and Epigenetic Factors
PARP Inhibitor
Market Overview
Comparative Analysis of Pipeline & Marketed Products
Marketed Drug Candidate Profiles
Zejula: Tesaro
Product Description
Research and Development
Zejula Heat Map
Product Development Activities
Zejula Heat Map
Forecasted Sales for Zejula
Zejula Analyst Insights
(The list continues)
Market Positioning of PARP Inhibitors
PARP Inhibitors Market Evolution
PARP Inhibitors Class Share Evolution
Pipeline Therapeutics
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Veliparib: Abbvie
Product Description
Research and Development
Product Development Activities
Forecasted Sales for Veliparib
Veliparib Analyst Insights
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Appendix
LIST OF TABLES
Table 1: Marketed and Pipeline products for PARP Inhibitors
Table 2: Forecasted Sales for Zejula (2018-2023)
Table 3: Historical and Forecasted Sales for Lynparza (2014-2023)
Table 4: Forecasted Sales for Rubraca (2018-2023)
Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment
Table 6: Total Drugs for PARP Inhibitors
Table 7: Late Stage Products (Phase III)
Table 8: Forecasted Sales for Veliparib (2018-2023)
Table 9: Forecasted Sales for Talazoparib (2018-2023)
Table 10: Mid Stage Products (Phase II)
Table 11: Early Stage Products (Phase I)
Table 12: Pre-clinical Stage Products
Table 13: Assessment by Monotherapy Products for PARP Inhibitors
Table 14: Assessment by Route of Administration for PARP Inhibitors
Table 15: Assessment by Stage and Route of Administration for PARP Inhibitors
Table 16: Dormant Products
Table 17: Discontinued Products
Table 1: Marketed and Pipeline products for PARP Inhibitors
Table 2: Forecasted Sales for Zejula (2018-2023)
Table 3: Historical and Forecasted Sales for Lynparza (2014-2023)
Table 4: Forecasted Sales for Rubraca (2018-2023)
Table 5: Cross Trial Comparison of PARP Inhibitors in maintenance Ovarian Cancer treatment
Table 6: Total Drugs for PARP Inhibitors
Table 7: Late Stage Products (Phase III)
Table 8: Forecasted Sales for Veliparib (2018-2023)
Table 9: Forecasted Sales for Talazoparib (2018-2023)
Table 10: Mid Stage Products (Phase II)
Table 11: Early Stage Products (Phase I)
Table 12: Pre-clinical Stage Products
Table 13: Assessment by Monotherapy Products for PARP Inhibitors
Table 14: Assessment by Route of Administration for PARP Inhibitors
Table 15: Assessment by Stage and Route of Administration for PARP Inhibitors
Table 16: Dormant Products
Table 17: Discontinued Products
LIST OF FIGURES
Figure 1: Structural and functional characteristics of PARP1
Figure 2: PARP Family of Proteins
Figure 3: Role of PARP1 in Base Excision Repair (BER)
Figure 4: Role of PARP1 in Transcription Regulation
Figure 5: PARP Inhibition
Figure 6: Marketed and Pipeline products for PARP Inhibitors
Figure 7: Forecasted Sales for Zejula (2018-2023)
Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)
Figure 9: Forecasted Sales for Rubraca (2018-2023)
Figure 10: Market Evolution of PARP Inhibitors (2014-2023)
Figure 11: Total Drugs for PARP Inhibitors
Figure 12: Late Stage Products (Phase III)
Figure 13: Forecasted Sales for Veliparib (2018-2023)
Figure 14: Forecasted Sales for Talazoparib (2018-2023)
Figure 15: Mid Stage Products (Phase II)
Figure 16: Early Stage Products (Phase I)
Figure 17: Pre-clinical Stage
Figure 18: Assessment by Monotherapy
Figure 19: Assessment by Route of Administration
Figure 20: Assessment by Stage and Route of Administration
Figure 21: Dormant Products
Figure 22: Discontinued Products
Figure 1: Structural and functional characteristics of PARP1
Figure 2: PARP Family of Proteins
Figure 3: Role of PARP1 in Base Excision Repair (BER)
Figure 4: Role of PARP1 in Transcription Regulation
Figure 5: PARP Inhibition
Figure 6: Marketed and Pipeline products for PARP Inhibitors
Figure 7: Forecasted Sales for Zejula (2018-2023)
Figure 8: Historical and Forecasted Sales for Lynparza (2014-2023)
Figure 9: Forecasted Sales for Rubraca (2018-2023)
Figure 10: Market Evolution of PARP Inhibitors (2014-2023)
Figure 11: Total Drugs for PARP Inhibitors
Figure 12: Late Stage Products (Phase III)
Figure 13: Forecasted Sales for Veliparib (2018-2023)
Figure 14: Forecasted Sales for Talazoparib (2018-2023)
Figure 15: Mid Stage Products (Phase II)
Figure 16: Early Stage Products (Phase I)
Figure 17: Pre-clinical Stage
Figure 18: Assessment by Monotherapy
Figure 19: Assessment by Route of Administration
Figure 20: Assessment by Stage and Route of Administration
Figure 21: Dormant Products
Figure 22: Discontinued Products
